APA (7th ed.) Citation

H, M., P, M., V, M., E, S., L, K., P, D., . . . I, A. (2025). Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v. Journal for immunotherapy of cancer, 13(4), . https://doi.org/10.1136/jitc-2024-010736

Chicago Style (17th ed.) Citation

H, Matuskova, et al. "Novel PD-1-targeted, Activity-optimized IL-15 Mutein SOT201 Acting in Cis Provides Antitumor Activity Superior to PD1-IL2v." Journal for Immunotherapy of Cancer 13, no. 4 (2025). https://doi.org/10.1136/jitc-2024-010736.

MLA (9th ed.) Citation

H, Matuskova, et al. "Novel PD-1-targeted, Activity-optimized IL-15 Mutein SOT201 Acting in Cis Provides Antitumor Activity Superior to PD1-IL2v." Journal for Immunotherapy of Cancer, vol. 13, no. 4, 2025, https://doi.org/10.1136/jitc-2024-010736.